DSM Sinochem Pharmaceuticals has initiated patent litigation against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company and CSPC Zhangnuo Pharmaceutical Company
DSM Sinochem Pharmaceuticals (DSP), produce and commercialise sustainable, enzymatic antibiotics, next generation statins and anti-fungals. It announced it has filed a lawsuit against three pharmaceutical companies for patent infringement.
DSM Sinochem Pharmaceuticals announced its wholly owned subsidiary, DSM Sinochem Pharmaceuticals Netherlands filed a lawsuit against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company for patent infringement in the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European Patent Number 1,610,766 B1.
This patent, which is owned by DSP, describes and claims amoxicillin trihydrate having a low free water content and processes for the manufacture thereof.
By its complaint, DSP seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, importation and sale of CSPC’s amoxicillin active pharmaceutical ingredient, and/or any drug product that utilises the active pharmaceutical, in the Netherlands.
Karl Rotthier, CEO at DSP, said: “DSP has a world class intellectual property (IP) portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology.
“After having previously filed patent litigation against Sinopharm Weiqida Pharmaceutical for patent infringement in India and the Netherlands in January 2017, DSP will continue to rigorously enforce its IP assets worldwide against any additional potential infringers as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”